India is set to capture a larger share of the global pharmaceutical market beyond generics, driven by the "China+1" strategy as companies diversify from China. Investments are pouring into India's affordable pharma services and growing infrastructure. India and Singapore are leading hubs for healthcare innovation, with Asia's healthcare market projected to reach USD 5 trillion by 2030.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z8E3aNu
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» China+1 opens larger share for India in global pharma manufacturing beyond generics: BCG report
0 comments:
Post a Comment